Home » Reports » Broker Ratings » Hikma Pharmaceuticals Plc 12.5% Potential Upside Indicated by Goldman Sachs
broker ratings

Hikma Pharmaceuticals Plc 12.5% Potential Upside Indicated by Goldman Sachs

Hikma Pharmaceuticals Plc using EPIC/TICKER code (LON:HIK) had its stock rating noted as ‘Downgrades’ with the recommendation being set at ‘NEUTRAL’ today by analysts at Goldman Sachs. Hikma Pharmaceuticals Plc are listed in the Health Care sector within UK Main Market. Goldman Sachs have set a target price of 1310 GBX on its stock. This indicates the analyst now believes there is a potential upside of 12.5% from today’s opening price of 1164 GBX. Over the last 30 and 90 trading days the company share price has decreased 231 points and decreased 518 points respectively. The 52 week high share price is 2346 GBX while the 52 week low for the stock is 1101 GBX.

Hikma Pharmaceuticals Plc has a 50 day moving average of 1,453.51 GBX and a 200 day moving average of 1,785.64. There are currently 240,123,805 shares in issue with the average daily volume traded being 683,560. Market capitalisation for LON:HIK is £2,811,849,757 GBP.

You might also find these articles of interest:

Register here to be notified of future articles like this
Get all our broker ratings on Twitter as they are published!